Characterization of the efficacies of osimertinib and nazartinib against cells expressing clinically relevant epidermal growth factor receptor mutations.

about

Characterization of the efficacies of osimertinib and nazartinib against cells expressing clinically relevant epidermal growth factor receptor mutations.

Item

http://www.wikidata.org/entity/Q47139649

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Characterization of the effica ...... wth factor receptor mutations.

@en

Characterization of the effica ...... wth factor receptor mutations.

@nl

type

Item

label

Characterization of the effica ...... wth factor receptor mutations.

@en

Characterization of the effica ...... wth factor receptor mutations.

@nl

prefLabel

Characterization of the effica ...... wth factor receptor mutations.

@en

Characterization of the effica ...... wth factor receptor mutations.

@nl

P1476

Characterization of the effica ...... wth factor receptor mutations.

@en

P2093

Hiroyuki Yasuda

http://www.w3.org/2001/XMLSchema#string

Ichiro Kawada

http://www.w3.org/2001/XMLSchema#string

Junko Hamamoto

http://www.w3.org/2001/XMLSchema#string

Katsuhiko Naoki

http://www.w3.org/2001/XMLSchema#string

Keita Masuzawa

http://www.w3.org/2001/XMLSchema#string

Kenzo Soejima

http://www.w3.org/2001/XMLSchema#string

Shigenari Nukaga

http://www.w3.org/2001/XMLSchema#string

Tomoko Betsuyaku

http://www.w3.org/2001/XMLSchema#string

Toshiyuki Hirano

http://www.w3.org/2001/XMLSchema#string

P2860

An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP

Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants

Structures of Lung Cancer-Derived EGFR Mutants and Inhibitor Complexes: Mechanism of Activation and Insights into Differential Inhibitor Sensitivity

Structural, Biochemical, and Clinical Characterization of Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations in Lung Cancer

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.

EGFR mutation and resistance of non-small-cell lung cancer to gefitinib.

AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer.

Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M.

P304

105479-105491

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.18632/ONCOTARGET.22297

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-11-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29285266

http://www.w3.org/2001/XMLSchema#string

P932

5739653

http://www.w3.org/2001/XMLSchema#string